| Detected | Trial | Change |
|---|---|---|
| 2026-06-11 | NCT05100862 A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants… |
Sponsor changed: BeiGene -> BeOne Medicines |
| 2026-06-04 | NCT07277231 A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With… |
Trial sites expanded: 46 -> 66 locations |
| 2026-05-28 | NCT07277231 A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With… |
Trial sites expanded: 29 -> 46 locations |
| 2026-05-23 | NCT07271667 A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in… |
Trial sites expanded: 3 -> 7 locations |
| 2026-05-15 | NCT07341191 Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma… |
Recruitment opened |
| 2026-05-15 | NCT04458610 Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic… |
date change Primary completion pushed: 2026-05-26 -> 2027-05-26 |
| 2026-05-15 | NCT04458610 Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic… |
date change Completion pushed: 2026-05-26 -> 2027-05-26 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-10 | NCT07638722 Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating… | Phase 2 | Not Yet Recruiting |
| 2026-05-19 | NCT07594899 AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06651970 | Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL… | Chronic Lymphocytic Leukaemia | Recruiting |
| Phase 3 | |||
| NCT07377578 | A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With… | Mantle Cell Lymphoma | Recruiting |
| NCT06428019 | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT06136559 | A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT05976763 | Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for… | Mantle Cell Lymphoma | Recruiting |
| NCT06742996 | A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared… | Mantle Cell Lymphoma | Recruiting |
| NCT07277231 | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT05100862 | A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants… | Relapsed/Refractory Follicular Lymphoma | Recruiting |
| NCT07321652 | Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment… | Chronic Lymphocytic Leukemia | Not Yet Recruiting |
| NCT04075292 | Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With… | Untreated Chronic Lymphocytic Leukemia | Active, Not Recruiting |
| NCT03336333 | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With… | Chronic Lymphocytic Leukemia | Active, Not Recruiting |
| NCT04529772 | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB… | Diffuse Large B-Cell Lymphoma | Active, Not Recruiting |
| NCT05735834 | Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated… | Splenic Marginal Zone Lymphoma | Active, Not Recruiting |
| NCT02970318 | A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or… | Chronic Lymphocytic Leukemia | Active, Not Recruiting |
| NCT04662255 | Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With… | Lymphoma, Mantle-Cell | Active, Not Recruiting |
| NCT04002297 | A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With… | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | Active, Not Recruiting |
| NCT05057494 | A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in… | Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Active, Not Recruiting |
| NCT02477696 | Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With… | Chronic Lymphocytic Leukemia | Active, Not Recruiting |
| NCT02972840 | A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously… | Lymphoma, Mantle Cell | Active, Not Recruiting |
| NCT06073821 | Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax… | CLL | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT05707377 | A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary… | Primary Membranous Nephropathy | Active, Not Recruiting |
| Phase 2 | |||
| NCT04505254 | Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | Recruiting |
| NCT06054776 | Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory… | Mantle Cell Lymphoma | Recruiting |
| NCT07014917 | Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL | Chronic Lymphocytic Leukemia | Recruiting |
| NCT06647732 | Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue… | Mucosa-associated Lymphoid Tissue Lymphoma (MALT) | Recruiting |